Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE)

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. TPS1126
• Main Authors: Aaron, Megan, White, Lia, D'Andrea, Kurt, Narayan, Vivek, Knollman, Hayley Michelle, Bradbury, Angela R., Tung, Nadine M., Robson, Mark E., Nathanson, Katherine, Domchek, Susan M., Shah, Payal Deepak
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2023

TPS1126Background: Hormone receptor-positive (HR+) metastatic breast cancer (MBC) in patients (pts) with germline or somatic BRCA1 or BRCA2 (g/sBRCA1/2) mutations has dual drivers: hormone receptor signaling and homologous recombination deficiency. The PALOMA-3 trial showed superiority of fulvestran...